---
title: The oxylipin analogue CS585 prevents platelet activation and thrombosis through
  activation of the prostacyclin receptor
date: '2023-08-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37624927/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230826181102&v=2.17.9.post6+86293ac
source: Blood
description: Cardiovascular disease remains the primary cause of morbidity and mortality
  globally. Platelet activation is critical for maintaining hemostasis and preventing
  leakage of blood cells from the vessel. There has been a paucity in the development
  of new drugs to target platelet reactivity. Recently, the oxylipin 12-HETrE, produced
  in the platelet, was shown to limit platelet reactivity through activation of the
  prostacyclin receptor. Here, we demonstrate the synthesis of a novel analogue ...
disable_comments: true
---
Cardiovascular disease remains the primary cause of morbidity and mortality globally. Platelet activation is critical for maintaining hemostasis and preventing leakage of blood cells from the vessel. There has been a paucity in the development of new drugs to target platelet reactivity. Recently, the oxylipin 12-HETrE, produced in the platelet, was shown to limit platelet reactivity through activation of the prostacyclin receptor. Here, we demonstrate the synthesis of a novel analogue ...